Publications by authors named "Yee Hong Chia"
Background: There are concerns that tamoxifen is less effective in Asian women because of the high prevalence of impaired function cytochrome P450 2D6 () polymor-phisms.
Aim: To evaluate how knowledge of genotype impacted the choice of hormonal agent and how genotype and agent were associated with clinical outcomes.
Methods: Eighty-two women were recruited.
Article Synopsis
- In the CheckMate 078 study, nivolumab showed better overall survival and safety compared to docetaxel in Chinese patients with previously treated advanced non-small cell lung cancer, with a minimum follow-up of three years.
- Patients treated with nivolumab had a 3-year overall survival rate of 19%, significantly higher than the 12% observed with docetaxel, and fewer experienced severe treatment-related side effects over time.
- Additionally, patients on nivolumab reported lower rates of disease-related symptom deterioration and improved quality of life, as measured by the Lung Cancer Symptom Scale.
Background: In the phase 3 CheckMate 078 study, nivolumab showed significant overall survival (OS) benefit and superior tolerability versus docetaxel in a predominantly Chinese patient population with non-small cell lung cancer (NSCLC). However, data on long-term outcomes with immunotherapy in Asian patients are limited. We report 2-year efficacy and safety data.
View Article and Find Full Text PDF